311 related articles for article (PubMed ID: 14986076)
1. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
Avritscher EB; Cantor SB; Shih YC; Escalante CP; Rivera E; Elting LS
Support Care Cancer; 2004 Jul; 12(7):531-6. PubMed ID: 14986076
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis.
Gómez-Outes A; Rocha E; Martínez-González J; Kakkar VV
Pharmacoeconomics; 2006; 24(1):81-92. PubMed ID: 16445305
[TBL] [Abstract][Full Text] [Related]
4. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.
Heerey A; Suri S
Pharmacoeconomics; 2005; 23(9):927-44. PubMed ID: 16153135
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis.
Caro JJ; Getsios D; Caro I; O'Brien JA
Pharmacoeconomics; 2002; 20(9):593-602. PubMed ID: 12141887
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
Trials; 2014 Dec; 15():502. PubMed ID: 25528663
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular weight heparin for deep vein thrombosis prophylaxis in hospitalized medical patients: results from a cost-effectiveness analysis.
Shorr AF; Jackson WL; Weiss BM; Moores LK
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):309-16. PubMed ID: 17473570
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.
Wilbur K; Lynd LD; Sadatsafavi M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):454-65. PubMed ID: 20699258
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
Gould MK; Dembitzer AD; Sanders GD; Garber AM
Ann Intern Med; 1999 May; 130(10):789-99. PubMed ID: 10366368
[TBL] [Abstract][Full Text] [Related]
13. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
Fiessinger JN; Lopez-Fernandez M; Gatterer E; Granqvist S; Kher A; Olsson CG; Söderberg K
Thromb Haemost; 1996 Aug; 76(2):195-9. PubMed ID: 8865530
[TBL] [Abstract][Full Text] [Related]
14. Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin.
de Lissovoy G; Yusen RD; Spiro TE; Krupski WC; Champion AH; Sorensen SV
Arch Intern Med; 2000 Nov; 160(20):3160-5. PubMed ID: 11074747
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
Martineau P; Tawil N
Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight versus unfractionated heparin. A clinical and economic appraisal.
Heaton D; Pearce M
Pharmacoeconomics; 1995 Aug; 8(2):91-9. PubMed ID: 10155614
[TBL] [Abstract][Full Text] [Related]
17. Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
Dunn CJ; Sorkin EM
Drugs; 1996 Aug; 52(2):276-305. PubMed ID: 8841743
[TBL] [Abstract][Full Text] [Related]
18. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
[TBL] [Abstract][Full Text] [Related]
19. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
Dunn CJ; Goa KL
Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
[TBL] [Abstract][Full Text] [Related]
20. [Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social].
Arreola-Ornelas H; Rosado-Buzzo A; García-Mollinedo L; Dorantes Aguilar J; Muciño-Ortega E; Mould-Quevedo JF
Cir Cir; 2012; 80(5):411-8. PubMed ID: 23351443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
